Ignyta 10-K 12 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	RXDX
Entity Registrant Name	IGNYTA, INC.
Entity Central Index Key	1557421
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	19,584,769
Entity Public Float		$146.50

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$6,345,663	$51,803,716
Short term investments	63,200,563
Prepaid expenses and other current assets	1,731,521	671,373
Total current assets	71,277,747	52,475,089
Fixed Assets - Net	6,280,909	830,706
Long term investments	7,086,700
Other Assets	658,716	13,045
Assets, Total	85,304,072	53,318,840
Current Liabilities
Accounts payable	975,264	811,600
Accrued expenses and other liabilities	4,929,601	590,235
Note payable, current portion	1,400,000
Lease payable, current portion	171,638
Warrant liability		129,400
Total current liabilities	7,476,503	1,531,235
Note payable, net of current portion and discount	18,830,136	8,950,000
Lease payable, net of current portion	344,188
Other liabilities	2,705,319	1,050,000
Total liabilities	29,356,146	11,531,235
Commitments and Contingencies (Note 11)
Stockholders' Equity
Preferred Stock, $.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding
Common Stock, $.0001 par value; 150,000,000 shares authorized: 19,584,769 and 13,934,876 shares issued and outstanding, respectively	1,958	1,393
Additional paid-in capital	111,561,894	57,359,152
Accumulated deficit	-55,562,586	-15,572,940
Accumulated other comprehensive loss	-53,340
Total stockholders' equity	55,947,926	41,787,605
Liabilities and Stockholders' Deficit, Total	$85,304,072	$53,318,840

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	150,000,000	150,000,000
Common Stock, shares issued	19,584,769	13,934,876
Common Stock, shares outstanding	19,584,769	13,934,876

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenue	$150,000
Expenses
Research and development	30,505,432	10,170,866
General and administrative	9,493,463	3,730,941
Loss from Operations	-39,848,895	-13,901,807
Other Income (Expense)
Other income (expense)	13,206	-105,952
Interest income (expense)	-141,627	-203,789
Total Other Income (Expense)	-128,421	-309,741
Loss Before Income Taxes	-39,977,316	-14,211,548
Income tax provision	12,330	2,095
Net Loss	-39,989,646	-14,213,643
Basic and diluted loss per share	($2.18)	($3.83)
Weighted average shares	18,327,757	3,711,885
Comprehensive Loss
Net loss	-39,989,646	-14,213,643
Unrealized loss on available for sale securities	-53,340
Comprehensive loss	($40,042,986)	($14,213,643)

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Total	Convertible Preferred Stock Series A [Member]	Convertible Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2012	$4,560,768	$84	$183	$65	$5,919,733	($1,359,297)
Balance (in shares) at Dec. 31, 2012		833,334	1,835,000	653,334
Issuance of Common Stock due to stock options exercised	3,000			1	2,999
Issuance of Common Stock due to stock options exercised (in shares)	12,290			12,290
Issuance of Restricted Stock due to Actagene merger	5,700			158	5,542
Issuance of Restricted Stock due to Actagene merger (in shares)				1,583,336
Conversion of Common Stock due to reverse merger		-84	-183	267
Conversion of Common Stock due to reverse merger (in shares)		-833,334	-1,835,000	2,675,678
Issuance of Stock net in offering costs	51,013,741			902	51,012,839
Issuance of Stock net in offering costs (in shares)				9,010,238
Stock-based compensation expense	370,439				370,439
Issuance of Warrant	47,600				47,600
Net loss	-14,213,643					-14,213,643
Balance at Dec. 31, 2013	41,787,605			1,393	57,359,152	-15,572,940
Balance (in shares) at Dec. 31, 2013				13,934,876
Issuance of Common Stock due to stock options exercised	6,900			2	6,898
Issuance of Common Stock due to stock options exercised (in shares)	18,143			18,143
Repurchase of Restricted Stock	-1,440			-40	-1,400
Repurchase of Restricted Stock (in shares)				-400,000
Issuance of Stock net in offering costs	51,581,842			603	51,581,239
Issuance of Stock net in offering costs (in shares)				6,031,750
Stock-based compensation expense	2,282,605				2,282,605
Issuance of Warrant	208,400				208,400
Reclass of warrant liability due to removal of anti-dilution provision	125,000				125,000
Unrealized loss on available for sale securities	-53,340						-53,340
Net loss	-39,989,646					-39,989,646
Balance at Dec. 31, 2014	$55,947,926			$1,958	$111,561,894	($55,562,586)	($53,340)
Balance (in shares) at Dec. 31, 2014				19,584,769

Statements_of_Stockholders_Equ1

Statements of Stockholders' Equity (Parenthetical) (Common Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Common Stock [Member]
Issuance of Stock, offering costs	$3,608,670	$3,047,687

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($39,989,646)	($14,213,643)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	527,675	112,380
Loss on sale of assets	4,141	29,351
Stock-based compensation	2,282,605	370,439
Change in fair value of warrant liabilities	-4,400	76,600
Accretion and amortization on debt securities	887,459
Warrant issued for license agreement		47,600
Amortization of non-cash financing costs	368,438	153,482
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets	-800,721	-672,569
Accounts payable trade	163,664	519,645
Accrued expenses and other liabilities	4,072,944	503,643
Net cash used in operating activities	-32,487,841	-13,073,072
Cash Flows From Investing Activities
Purchases of investments	-89,286,432
Sales of investments	18,058,370
Purchases of fixed assets	-3,117,375	-687,960
Proceeds received from sale of assets	15,500	10,000
Net cash used by investing activities	-74,329,937	-677,960
Cash Flows From Financing Activities
Net proceeds from issuance of Common Stock	51,581,842	51,013,741
Proceeds from issuance of notes payable	21,000,000	11,000,000
Payments on notes payable	-10,000,000	-1,500,000
Payment of deferred financing costs	-1,050,000
Payment of financing costs	-155,000
Payments on leases payable	-22,577
Net (repurchase)/proceeds from issuance of Restricted Stock	-1,440	5,700
Net proceeds from stock options exercised	6,900	3,000
Net cash provided by financing activities	61,359,725	60,522,441
Net Change in Cash and Cash Equivalents	-45,458,053	46,771,409
Cash and Cash Equivalents at Beginning of Period	51,803,716	5,032,307
Cash and Cash Equivalents at End of Period	6,345,663	51,803,716
Supplemental Disclosures of Cash Flow Information:
Interest	1,884,353	51,122
Income taxes	5,304	2,095
Noncash investing and Financing Activities:
Warrants issued with debt financing recorded as debt discount	208,400	28,300
Final loan fee recorded as debt discount	630,000	1,050,000
Leased capital equipment	538,403
Leasehold improvement paid by landlord	2,341,741
Warrant reclass due to removal of anti-dilution provision	125,000
Unrealized loss on available for sale securities	$53,340

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies	A summary of the Company’s significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.
	Nature of operations	Ignyta, Inc. (“Ignyta”) was founded in 2011 and is incorporated in the state of Delaware. On June 12, 2014, Ignyta, Inc., a corporation incorporated in the state of Nevada, merged with and into Ignyta (then known as Ignyta Operating, Inc.) with Ignyta Operating, Inc. surviving the merger and changing its name to Ignyta, Inc. (see Note 2).
		On October 31, 2013, Ignyta merged with and into IGAS Acquisition Corp., a wholly-owned subsidiary of Ignyta, Inc., a Nevada corporation previously named Infinity Oil & Gas Company (see Note 2). As used in these financial statements, unless the context indicates or otherwise requires, the “Company”, “we”, “us”, and “our” refer to Ignyta.
		In May 2013, the Company acquired Actagene Oncology, Inc. (“Actagene”), a San Diego based privately held biotechnology company developing precision medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. With the acquisition, the Company changed its business strategy from a prior focus on molecular diagnostics for autoimmune disease to an integrated drug and diagnostic, or Rx/Dx, focus on drug and biomarker discovery and development for oncology (see Note 3).
		The Company is a precision oncology biotechnology company dedicated to discovering or acquiring, then developing and commercializing, targeted new drugs for cancer patients whose tumors harbor specific molecular alterations. The Company is pursuing an integrated therapeutic and diagnostic, or Rx/Dx, strategy, where it anticipates pairing each of its product candidates with biomarker-based companion diagnostics that are designed to identify the patients who are most likely to benefit from the precisely targeted drugs the Company develops.
	Liquidity	As of December 31, 2014, the Company had an accumulated deficit of approximately $55,563,000. The Company also had negative cash flow from operations of approximately $32,488,000 during the twelve months ended December 31, 2014.
		The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products.
		We are currently focused primarily on the development of our entrectinib, RXDX-103 and Spark programs. We believe such activities will result in our continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of our products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing. We cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
		While we expect that our existing cash, cash equivalents and available-for-sale securities will enable us to fund our operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require us to delay, reduce, limit or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
	Use of estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation allowance on deferred tax assets, the valuation of warrants, the useful life of assets and those assumed in calculating stock-based compensation expense.
	Cash and cash equivalents	The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
	Investments	Investments consist of corporate notes and bonds and commercial paper. The Company classifies investments as available-for-sale at the time of purchase. All investments are recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investments as of each balance sheet date to assess whether those with unrealized loss positions are other-than-temporarily impaired. Impairments are considered to be other-than-temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of its cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the Statements of Operations. No other-than-temporary impairment charges have been recognized since inception.
	Fixed assets	Fixed assets are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to seven years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
	Impairment of long-lived assets	In accordance with authoritative guidance related to impairment or disposal of long-lived assets, management reviews the Company’s long-lived asset groups for impairment whenever events indicate that their book value may not be recoverable. When management determines that one or more impairment indicators are present for an asset group, it compares the book value of the asset group to net future undiscounted cash flows that the asset group is expected to generate. If the book value of the asset group is greater than the net future undiscounted cash flows that the asset group is expected to generate, it compares the fair value to the book value of the asset group. If the fair value is less than the book value, it recognizes an impairment loss. The impairment loss would be the excess of the book value of the asset group over its fair value. To date, the Company has not experienced any impairment losses on its long-lived assets used in operations.
	Stock-based compensation	The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
		The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
	Fair value of financial instruments	The Company’s financial instruments consist of cash and cash equivalents, investments, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of December 31, 2014 and December 31, 2013, the book values are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Derivative liabilities	The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future events, expected volatility, expected life, yield, and risk free interest rate.
	Income taxes	Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
	Earnings per share (“EPS”)	Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted EPS calculations are the same since the increased number of shares that would be included in the diluted calculation from the assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the financial statements.
	Comprehensive income (loss)	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported net of their related tax effect, to arrive at comprehensive income (loss).
	Research and development costs	The Company is actively engaged in new product development efforts for which related costs are expensed as incurred.
	Fair value measurement	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
		The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013 (in thousands):
			December 31, 2014								December 31, 2013
			Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents		$	6,346	$	—	$	—	$	6,346	$	51,804	$	—	$	—	$	51,804
	Short-term investments:
	Corporate debt securities
	Financial			—		34,788		—		34,788		—		—		—		—
	Industrial			—		17,503		—		17,503		—		—		—		—
	Utility			—		7,014		—		7,014		—		—		—		—
	Commercial paper
	Financial			—		3,896		—		3,896		—		—		—		—
	Industrial			—		—		—		—		—		—		—		—
	Total short-term investments		$	—	$	63,201	$	—	$	63,201	$	—	$	—	$	—	$	—
	Long-term investments:
	Corporate debt securities
	Financial			—		3,230		—		3,230		—		—		—		—
	Industrial			—		3,857		—		3,857		—		—		—		—
	Utility			—		—		—		—		—		—		—		—
	Total long-term investments		$	—	$	7,087	$	—		7,087	$	—	$	—	$	—	$	—
	Total assets measured at fair value		$	6,346	$	70,288	$	—	$	76,634	$	51,804	$	—	$	—	$	51,804
	Liabilities:
	Warrant liability			—		—		—		—		—		—		129		129
	Total liabilities measured at fair value		$	—	$	—	$	—	$	—	$	—	$	—	$	129	$	129
		The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its debt securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.
		The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The warrants were reclassified to equity during the year due to the removal of the anti dilution provision in the Articles of Incorporation as referenced in the warrant agreements (see Note 9).

Reverse_Merger

Reverse Merger	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Reverse Merger	2. Reverse Merger	For purposes of the below descriptions in this Note 2, all references to “Ignyta” shall refer to Ignyta, Inc., a Nevada corporation whose name was changed from Infinity Oil & Gas Company on October 31, 2013 in connection with the closing of the Merger; and all references to “Merger Sub” shall refer to IGAS Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Ignyta.
		On October 31, 2013, Ignyta, Merger Sub, and the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). The Merger Agreement provided for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the transaction as a wholly owned subsidiary of Ignyta. The Merger closed on October 31, 2013 concurrently with the execution and delivery of the Merger Agreement.
		Also on October 31, 2013, prior to the execution and delivery of the Merger Agreement and the concurrent closing of the Merger, (i) the holders of all series of outstanding preferred stock of the Company, consisting of Series A Preferred Stock and Series B Preferred Stock, voluntarily converted such shares into shares of the Company’s common stock in accordance with the certificate of incorporation of the Company and at the then-effective conversion rates therefor, which were one-to-one in all cases, and (ii) the Company amended its certificate of incorporation to change its name to “Ignyta Operating, Inc.” and to effect a three-to-one reverse stock split of its capital stock, resulting in 4,916,469 outstanding shares of the Company’s common stock, outstanding warrants to acquire up to an aggregate of 25,001 shares of the Company’s common stock, and outstanding options granted under the Company’s 2011 Stock Incentive Plan (as amended and restated, the “2011 Plan”) to purchase up to an aggregate of 358,986 shares of the Company’s common stock.
		At the closing of the Merger and pursuant to the terms of the Merger Agreement, Ignyta issued an aggregate of 4,916,469 shares of its common stock to the former stockholders of the Company in exchange for all of the outstanding shares of the Company’s capital stock. That number of shares was negotiated and agreed to by Ignyta and the Company prior to entering into the Merger Agreement. As of immediately following the closing of the Merger, the Company became a wholly-owned subsidiary of Ignyta, and the former stockholders of the Company collectively owned approximately 99.85% of the outstanding shares of Ignyta’s common stock. In addition, pursuant to the terms of the Merger Agreement, as of the closing of the Merger Ignyta assumed (i) the 2011 Plan, under which an aggregate of 342,209 shares were reserved for issuance pursuant to future equity grants, (ii) the obligation to issue up to an aggregate of 358,986 shares of its common stock upon the exercise of all options granted under the 2011 Plan that were outstanding as of immediately prior to the closing of the Merger, and (iii) the obligation to issue up to an aggregate of 25,001 shares of its common stock upon the exercise of two warrants previously issued by the Company and outstanding as of immediately prior to the closing of the Merger.
		On June 12, 2014, Ignyta merged with and into the Company, with the Company surviving the merger and changing its name to Ignyta, Inc. (the “Reincorporation Merger”). At the closing of the Reincorporation Merger, (i) each outstanding share of Ignyta’s common stock was converted into one share of common stock of the Company, (ii) each outstanding option to purchase, or other equity award relating to, Ignyta’s common stock was deemed to constitute an option to purchase, or other equity award relating to, common stock of the Company with no change in the exercise price or other terms or provisions of the award, (iii) the shares of Ignyta’s common stock that remained available for issuance under the 2011 Plan and the 2014 Incentive Award Plan (the “2014 Plan,” and, together with the 2011 Plan, the “Ignyta Plans”), were deemed to relate to shares of the Company’s common stock, and (iv) each outstanding warrant to purchase Ignyta’s common stock was deemed to constitute a warrant to purchase an equal number of shares of common stock of the Company with no change in the exercise price or other terms or provisions of the warrant.

Actagene_Merger

Actagene Merger	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Actagene Merger	3. Actagene Merger	In May 2013, the Company entered into an Agreement and Plan of Reorganization with Actagene. In accordance with the agreement, Actagene was merged into the Company and the separate corporate existence of Actagene ceased, with the Company continuing as the surviving corporation. On May 20, 2013, the merger was effected and the Company issued 1,583,336 shares of restricted common stock in exchange for the cancellation of all of the outstanding shares of Actagene.
		The merger was accounted for as a combination of entities under common control. The majority stockholder of the Company was also the majority stockholder of Actagene, with approximately 60% of the voting power in each entity. Additionally, representatives of the majority stockholder controlled the day to day operations and were on the board of directors of each entity.

Investments

Investments	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Investments	4. Investments	The Company determines the appropriate designation of investments at the time of purchase and reevaluates such designation as of each balance sheet date. As of December 31, 2014, the Company’s short-term investments have maturity dates of less than one year from the balance sheet date. The Company’s long-term investments have maturity dates of greater than one year from the balance sheet date.
		The cost of securities sold is based on the specific identification method. Amortization of premiums, accretion of discounts, interest, dividend income, and realized gains and losses are included in investment income.
		The following table summarizes investments by security type as of December 31, 2014:
			December 31, 2014 (in thousands)
			Cost		Gross		Gross			Fair
					Unrealized		Unrealized			Market
					Gains		Losses			Value
	Available-for-sale securities:
	Corporate debt securities, short-term		$	63,239	$	—	$	(38	)	$	63,201
	Corporate debt securities, long-term		$	7,102	$	—	$	(15	)	$	7,087
	Total		$	70,341	$	—	$	(53	)	$	70,288

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Fixed Assets	5. Fixed Assets	Fixed assets consisted of the following:
			December 31,			December 31,
			2014			2013
	Manufacturing and lab equipment		$	3,837,967		$	775,872
	Office furniture			278,895			59,095
	Computers and equipment			358,964			110,857
	Software			112,451			—
	Leasehold Improvements			2,326,963			—
				6,915,240			945,824
	Less accumulated depreciation and amortization			(634,331	)		(115,118	)
			$	6,280,909		$	830,706
		Depreciation expense for years ended December 31, 2014 and 2013 was $527,675 and $112,380, respectively.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable	On September 30, 2014 the Company entered into an amended and restated loan and security agreement (the “New Loan Agreement”) with a financial institution. The New Loan Agreement replaced the prior loan and security agreement (the “Loan Agreement”) which was first entered into in June 2012, amended in February 2013 and amended and restated in December 2013. The amount borrowed under the New Loan Agreement was increased from $10,000,000 to $21,000,000, with an option to receive an additional $10,000,000, which may be drawn down at any time prior to September 30, 2015 provided the Company has initiated the Phase IIa portion of its ongoing, global Phase I/II clinical study of entrectinib and subject to other customary conditions for funding. All principal and interest due on the prior Loan Agreement was paid in full and the Company was advanced the net proceeds on September 30, 2014. This transaction was accounted for as a debt modification. Payments of principal and interest are due on the New Loan Agreement on a fully amortized basis of 30 months in equal monthly installments, commencing after a twelve-month period of interest only payments, such that all amounts owed under the New Loan Agreement will mature on April 1, 2018. The number of months of interest-only payments and the number of months over which the principal will be amortized each will be increased by six months if the second loan tranche has been drawn down or the Company has raised net proceeds of at least $50 million through the offering of its equity securities, in each case prior to October 31, 2015. Upon the final maturity date, the Company will also owe to the lender a final payment equal to 3% of the full principal amount under the New Loan Agreement. The final payment of $630,000, which is based on the initial amount borrowed under the New Loan Agreement, is presented as a debt discount on the related debt to be amortized to interest expense. Interest on the note was fixed on the date of funding at 8.56%. Pursuant to the New Loan Agreement, the Company is bound by certain affirmative and negative covenants setting forth actions that it must and must not take during the term thereof. Upon the occurrence of an event of default under the New Loan Agreement, subject to cure periods for certain events of default, all amounts owed by the Company thereunder shall begin to bear interest at a rate of 11.56% and may be declared immediately due and payable by SVB. The Company has granted SVB a security interest in substantially all of its personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to SVB under the New Loan Agreement. The Company has also agreed not to encumber any of its intellectual property without SVB’s prior written consent.
		In connection with entering into the New Loan Agreement, the Company issued to SVB and its affiliate warrants to purchase an aggregate of 37,849 shares of its common stock. The warrants are exercisable immediately, have a per-share exercise price of $7.518 and have a term of seven years. The warrants were recorded at a fair value of $208,400 and are presented as a debt discount on the related debt to be amortized to interest expense over the term of the Loan Agreement (See Note 9). If the Company draws down the second loan tranche, at that time it will issue to SVB and its affiliate additional warrants which will be exercisable immediately and have a term of seven years. Those warrants will be exercisable for an aggregate number of shares equal to $135,500 divided by the lower of (a) the trailing 10-day average of the closing price of the Company’s common stock on the Nasdaq Capital Market prior to the funding date of the second loan tranche and (b) the closing price of the Company’s common stock on the Nasdaq Capital Market on the funding date of the second loan tranche, at an exercise price equal to such divisor.
		On December 31, 2013 the Company entered into the Loan Agreement. The Loan Agreement replaced the prior loan and security agreement (the “Prior Loan Agreement”) which was first entered into in June 2012 and amended in February 2013. The maximum borrowing amount under the Loan Agreement was increased from $1,500,000 to $10,000,000. On the maturity date, the Company also owed to the lender a final payment of $1,050,000 which was presented as a debt discount on the related debt. On September 30, 2014, in conjunction with the New Loan Agreement, this note along with the final loan payment of $1,050,000 was paid in full.
		As additional consideration for the cost and risk associated with the Prior Loan Agreement, the Company issued to the lender a warrant to purchase up to 8,334 shares of Series B Preferred Stock in June 2012, and an additional warrant to purchase up to a number of shares of Series B Preferred Stock equal to 5% of the amount loaned under the Prior Loan Agreement on February 27, 2013 and thereafter, subject to adjustment as set forth in the warrant, including without limitation for stock combinations and splits. As a result, following the final advance under the Prior Loan Agreement in July 2013, the warrant became exercisable for 16,667 shares of the Company’s Series B Preferred Stock. The warrants issued in 2013 and 2012 were recorded at fair values of $28,300 and $24,500, respectively, and were presented as a debt discount on the related debt to be amortized to interest expense over the term of the Prior Loan Agreement (See Note 9). Both warrants were assumed by Ignyta in connection with the Merger (see Note 2). As a result of the payoff of the original loan, the debt discount was written off on December 31, 2013.
		Interest expense due to amortization of the debt discounts for the years ended December 31, 2014 and 2013 was $287,863, and $48,470, respectively.
		Future minimum principal payments on notes payable are as follows:
	Twelve Months ending December 31,
	2015		$	1,400,000
	2016			8,400,000
	2017			8,400,000
	2018			2,800,000
	Total		$	21,000,000

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity	The Company is authorized to issue 150,000,000 shares of common stock and 10,000,000 shares of preferred stock, with the preferred stock having the rights, preferences and privileges that our Board of Directors may determine from time to time. Each share of the Company’s common stock is entitled to one vote, and all shares rank equally as to voting and other matters.
		On March 19, 2014, the Company completed a secondary public stock offering providing for the issuance and sale to investors of an aggregate of 6,031,750 shares of its common stock at a purchase price of nine dollars and fifteen cents ($9.15) per share for gross proceeds of approximately $55.2 million.
		On November 29, 2013, the Company completed a PIPE financing with 195 accredited investors, providing for the issuance and sale to such investors of an aggregate of 1,270,096 shares of its common stock at a purchase price of six dollars ($6.00) per share, for gross proceeds of approximately $7.6 million.
		On November 6, 2013, the Company completed a PIPE financing, providing for the issuance and sale of an aggregate of 7,740,142 shares of its common stock to 52 accredited investors at a purchase price of six dollars ($6.00) per share, for gross proceeds of approximately $46.4 million.
		On October 31, 2013, Ignyta, Inc. approved a 100-for-1 reverse stock split of its capital stock, and the Company approved a 3-for-1 reverse stock split of its capital stock (the “Reverse Stock Splits”). The par value of Ignyta, Inc.’s outstanding capital stock changed from $0.0001 to $0.00001 per share on such date. At the closing of the Reincorporation Merger, the par value of the Company’s outstanding capital stock changed back from $0.00001 to $0.0001 per share. The stockholders’ equity section of the accompanying financial statements and all share numbers disclosed throughout the financial statements have been retroactively adjusted to give effect to the Reverse Stock Splits and the Reincorporation Merger.
	Series A Convertible Preferred Stock	During 2012, the Company issued 416,667 shares of Series A Preferred Stock at $0.60 per share for proceeds consisting of $250,000 in cash.
		During 2011, the Company issued 416,667 shares of Series A Preferred Stock at $0.60 per share for proceeds consisting of $250,000 in cash.
		On October 31, 2013, prior to the Reverse Stock Splits, the holders of shares of the Company’s Series A Preferred Stock elected to convert all issued and outstanding shares of such preferred stock into shares of common stock at the applicable conversion rate, which was one-to-one.
	Series B Convertible Preferred Stock	During 2012, the Company issued 1,835,000 shares of Series B Preferred Stock at $3.00 per share for proceeds consisting of $5,505,000 in cash.
		On October 31, 2013, prior to the Reverse Stock Splits, the holders of shares of the Company’s Series B Preferred Stock elected to convert all issued and outstanding shares of such preferred stock into shares of common stock at the applicable conversion rate, which was one-to-one.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation	On June 11, 2014, the Company adopted the 2014 Plan. The 2014 Plan provides for the issuance of equity awards to employees and non-employees of 3,000,000 shares, plus one share for each share subject to a stock option that was outstanding under the 2011 Plan as of the effective date of the 2014 Plan that subsequently expires, is forfeited or is settled in cash.
		On February 28, 2014, the Company adopted the Employment Inducement Incentive Award Plan (the “Inducement Plan”). The Inducement Plan provided for the issuance of equity awards to new employees of 1,000,000 shares.
		In 2011, the Company adopted the 2011 Plan. The 2011 Plan provided for the issuance of incentive stock options to employees and nonstatutory stock options, restricted stock awards, stock appreciation rights and stock bonuses to directors, employees and consultants. In February 2013, October 2013 and December 2013, the 2011 Plan was amended to, among other things, increase the number of shares of the Company’s common stock available for issuance thereunder from 166,666 shares to 666,666 shares, to 712,652 shares and to 2,712,652 shares, respectively.
	Stock option activity	There are a total of 3,000,000 shares of common stock reserved under the 2014 Plan, plus one share for each share subject to a stock option that was outstanding under the 2011 Plan as of the effective date of the 2014 Plan that subsequently expires, is forfeited or is settled in cash. As of December 31, 2014, 2,233,319 shares remain available under the 2014 Plan. There were a total of 2,712,652 shares of common stock reserved under the 2011 Plan. Under applicable rules of the NASDAQ Stock Market, the Company may not make additional grants under the 2011 Plan unless the 2011 Plan is approved by the Company’s stockholders. The Company did not seek stockholder approval and adopted the 2014 Plan. There were a total of 1,000,000 shares of common stock reserved under the Inducement Plan. From and after the effective date of the 2014 Plan, no additional equity grants may be made by the Company under the 2011 Plan or the Inducement Plan.
		At the closing of the Reincorporation Merger, (i) each outstanding option to purchase, or other equity award relating to, Ignyta, Inc.’s common stock was deemed to constitute an option to purchase, or other equity award relating to, common stock of the Company with no change in the exercise price or other terms or provisions of the award, and (ii) the shares of Ignyta, Inc.’s common stock that remained available for issuance under the Ignyta Plans were deemed to relate to shares of the Company’s common stock.
		The options that are granted under the Ignyta Plans and the Inducement Plan are exercisable at various dates and will expire no more than ten years from their dates of grant. The exercise price of each option to be granted under the 2014 Plan shall be determined by the administrator of the 2014 Plan, which is the Company’s Board of Directors or the Compensation Committee thereof, and shall not be less than 100% of the fair market value of the Company’s common stock on the date the option is granted. Generally, options are granted with an exercise price equal to the fair market value of the Company’s common stock on the date of the option grant. For holders of more than 10% of the Company’s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company’s common stock on the date of grant and for a term not to exceed five years.
		A summary of the Company’s stock option activity and related information is as follows:
			Options			Weighted-			Weighted-		Aggregate
			Outstanding			Average			Average		Intrinsic
						Exercise			Remaining		Value
						Price			Contractual
									Term
	Balance at December 31, 2012			156,659		$	0.36			—	$	—
	Granted			1,061,325			4.6			—		—
	Exercised			(12,290	)		0.24			—		—
	Expired			(2,154	)		0.54			—		—
	Forfeited			(70,387	)		0.45			—		—
	Balance at December 31, 2013			1,133,153		$	4.33			9.71	$	3,026,430
	Granted			2,300,000			7.89			—		—
	Exercised			(18,143	)		0.38			—		—
	Expired			(4,999	)		0.58			—		—
	Forfeited			(418,355	)		7.43			—		—
	Balance at December 31, 2014			2,991,656		$	6.67			9.21	$	2,482,181
	Exercisable at December 31, 2014			369,705		$	3.59			8.55	$	1,212,411
		The fair value of options granted to employees and non-employee directors was estimated at the date of grant using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
			December 31,			December 31,
			2014			2013
	Risk free interest rate			1.83	%		1.92	%
	Dividend yield			0	%		0	%
	Volatility			65.24	%		59.26	%
	Weighted-average expected life of option (years)			6			6.1
		The estimated weighted-average per-share fair value of stock options granted to employees and non-employee directors for the years ended December 31, 2014 and 2013 was $4.70 and $2.83, respectively.
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
			December 31,			December 31,
			2014			2013
	Risk free interest rate			2.1	%		2.61	%
	Dividend yield			0	%		0	%
	Volatility			68.01	%		58.16	%
	Weighted-average expected life of option (years)			9.35			10
		The estimated weighted-average per-share fair value of stock options granted to non-employees for the years ended December 31, 2014 and 2013 was $6.65 and $1.59, respectively.
		Dividend Yield—The Company has never declared or paid dividends on common stock and has no plans to do so.
		Expected Volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated or is expected to fluctuate during a period. The Company considered the historical volatility of peer companies and business and economic considerations in order to estimate the expected volatility, due to the Company not being publicly traded for a significant period.
		Risk-Free Interest Rate—This is the U.S. Treasury rate for the day of each option grant during the quarter having a term that most closely resembles the expected life of the option.
		Expected Life of the Option Term—This is the period of time that the options granted are expected to remain unexercised. Options granted during the period have a maximum contractual term of ten years. The Company estimates the expected life of the option term based on the simplified method as defined in Staff Accounting Bulletin 110. For non-employee options granted, this is the remaining contractual term of the option as of the reporting date.
		Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company assesses the forfeiture rate on an annual basis and revises the rate when deemed necessary.
		Stock-based compensation expense for employees and non-employees for the years ended December 31, 2014 and 2013 was $2,056,027 and $351,159, respectively. For the years ended December 31, 2014 and 2013, $668,932 and $220,888 was recorded to research and development expense, respectively, and $1,387,095 and $130,271 was recorded to general and administrative expense, respectively.
		As of December 31, 2014, there was an additional $9,782,363 of total unrecognized compensation cost related to unvested stock-based awards granted under the Ignyta Plans and the Inducement Plan. This unrecognized compensation cost is expected to be recognized over a weighted-average period of 3.28 years.
	Restricted stock activity	In 2011, Ignyta sold 666,668 shares of restricted common stock for gross proceeds of $2,000 in accordance with restricted stock purchase agreements with various advisors. Approximately 600,000 shares were vested immediately and the remaining 66,668 are subject to vesting requirements based on future service.
		The terms of each of the agreements state that the Company has the right to repurchase the unvested shares of stock if the shareholder stops providing services to the Company. The Company repurchased 13,334 shares of common stock in 2012. The Company records stock-based compensation expense, calculated as the difference between the fair value of the common stock at each reporting period less the proceeds received, upon vesting of the restricted stock. Related stock-based compensation for the years ended December 31, 2014 and 2013 was $64,255 and $19,280, respectively. All stock-based compensation relating to restricted stock was expensed to research and development. At December 31, 2014, 639,337 shares were vested and 13,997 shares remained unvested.
		On May 20, 2013, in connection with Ignyta’s merger with Actagene, Ignyta issued 1,583,336 shares of restricted common stock in exchange for the cancellation of all of the outstanding shares of Actagene (see Note 3). In February of 2014, in connection with the termination of employment of an employee, the Company repurchased 400,000 restricted shares. Of the remaining restricted shares, approximately 1,000,000 shares were vested immediately and 183,336 are subject to vesting requirements based on future service. The shares vest over four years, with one-third having vested in February 2014 and the remaining unvested shares vesting over the next 36 months. Related stock-based compensation for the years ended December 31, 2014 and 2013 was $162,323, and $0, respectively. All stock-based compensation relating to restricted stock was expensed to research and development. At December 31, 2014, 1,150,928 shares were vested and 32,408 shares remained unvested.
		All of the foregoing restricted stock was exchanged for shares of Ignyta, Inc. common stock in connection with the Merger and for the Company’s common stock in connection with the Reincorporation Merger (see Note 2).

Warrants

Warrants	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants	9. Warrants	On September 30, 2014, the Company issued two warrants to acquire an aggregate of up to 37,849 shares of its common stock in connection with the New Loan Agreement. The warrants both have an exercise price of $7.518 per share and are exercisable at the option of the holder, in whole or in part, at any time until September 30, 2021. The terms of such warrants provide for adjustments in the event of certain stock dividends, stock splits, recapitalizations, reclassifications and consolidations.
		The Company valued the warrants at $208,400 in the aggregate using a binomial model with an exercise price of $7.518, risk free interest rate of 2.22%, volatility of 69.7%, and a useful life of 7 years. The entire amount was recorded as a debt discount on the related debt.
		On November 6, 2013, the Company issued Nerviano Medical Sciences S.r.l. (“NMS”) a warrant to acquire up to 16,667 shares of its common stock in connection with the license agreement between the Company and NMS. The warrant has an exercise price of $6.00 per share and is exercisable at the option of the holder, in whole or in part, at any time until November 6, 2018. The terms of such warrant provide for adjustments in the event of certain stock dividends, stock splits, recapitalizations, reclassifications and consolidations. Upon exercise, the aggregate exercise price of the warrant issued is payable by NMS in cash. The Company recognized warrant expense of $47,600 using a binomial model with an exercise price of $6.00, risk free interest rate of 1.68%, volatility of 54.8%, and a useful life of 4.85 years. The entire amount was expensed to research and development in 2013.
		During 2012, the Company issued a warrant to purchase 8,334 shares of Series B Preferred Stock in connection with the Prior Loan Agreement (see Note 6). The exercise price of the warrant is $3.00 per share.
		On February 27, 2013, the Company issued a warrant to purchase up to a number of shares of Series B Preferred Stock equal to 5% of the amount loaned under the Prior Loan Agreement on February 27, 2013 and thereafter, subject to adjustment as set forth in the warrant, including without limitation for stock combinations and splits (see Note 6). As a result, following the February 2013 and July 2013 advances under the Prior Loan Agreement, the warrant became exercisable for 16,667 shares of the Company’s Series B Preferred Stock. The exercise price of the warrant is $3.00 per share and the warrant expires February 27, 2020.
		The exercise price of the warrants issued in conjunction with the 2012 and 2013 loan financings were previously protected against dilutive financing through the term of the warrants. Pursuant to ASC 815-15 and ASC 815-40, the fair value of the warrants were recorded as derivative liabilities on the issuance dates. The warrants were reclassified in 2014 due to the removal of the anti-dilution provisions, resulting in approximately $125,000 being reclassified to equity.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes	As of December 31, 2014 and 2013, a non-current deferred tax asset of approximately $22,828,000 and $6,008,000, respectively, had been recognized for the temporary differences primarily related to federal and state net operating losses and research and development credits.
		A valuation allowance has been recorded to fully offset the deferred tax asset as it is more likely than not that the assets will not be fully utilized. The valuation allowance at December 31, 2014 was approximately $22,828,000 and increased by approximately $16,820,000 during 2014.
		At December 31, 2014, the Company had unused federal and state net operating losses of approximately $33,015,000 and $32,134,000, respectively.
		The federal and California net operating loss carryforwards will begin to expire in 2031. Florida and Massachusetts will begin to expire in 2034. At December 31, 2014, we also had federal and California state research tax credit carryforwards of approximately $794,000 and $859,000, respectively. The federal carryforwards begin to expire in 2031 and the California carryforwards have no expiration.
		Pursuant to Internal Revenue Code sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within a three-year period. These financial statements do not contain any adjustment relating to such potential limitations.
		The Company is subject to tax in the United States and in the state of California, Florida and Massachusetts. As of December 31, 2014, the Company’s tax years from inception are subject to examination by the tax authorities. The Company is not currently under examination by any U.S. federal or state jurisdictions.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies
	Capital leases	During 2014, the Company entered into capital lease agreements for the purchase of certain lab equipment. As of December 31, 2014, property held under the current capital leases was as follows:
			December 31,
			2014
	Lab equipment		$	635,730
				635,730
	Less accumulated depreciation and amortization			(16,716	)
	Total		$	619,014
		Depreciation expense related to the capital lease equipment for the years ended December 31, 2014 and 2013 was $16,716 and $0, respectively.
		As of December 31, 2014, future minimum payments under all capital leases are as follows:
	Twelve Months ending December 31,		Lease Payment
	2015		$	194,002
	2016			194,002
	2017			167,474
	Total minimum payments		$	555,478
	Less amounts representing interest			(39,652	)
	Present value of net minimum payments		$	515,826
	Less current portion			(171,638	)
	Long-term capital lease obligations		$	344,188
	Operating leases	The Company leases office space under non-cancelable operating leases expiring on various dates through October 2019. Rent expense under those operating leases for the years ended December 31, 2014 and 2013 was $406,357 and $146,952, respectively.
		The Company leases lab equipment under a non-cancelable operating lease that expires in March 2016. Monthly payments are $5,758. Rent expense under that operating lease for the years ended December 31, 2014 and 2013 was $88,504 and $60,620, respectively.
		Future minimum lease payments required under the operating leases are as follows:
	Twelve Months Ending December,
	2015		$	712,400
	2016			770,500
	2017			769,900
	2018			793,000
	2019			679,300
	Thereafter			—
	Total		$	3,725,100
	License agreements	We entered into a license agreement with NMS on October 10, 2013, which was amended on October 25, 2013, became effective on November 6, 2013, and was amended December 12, 2014. The agreement grants us exclusive global rights to develop and commercialize entrectinib, as well as a second product candidate, RXDX-102. As a result of the Phase I results relating to entrectinib that we have seen to date, we designated RXDX-102 as a back-up compound to entrectinib. Accordingly, we will not devote further development resources to RXDX-102.
		Our development rights under the license agreement are exclusive for the term of the agreement with respect to entrectinib and RXDX-102 and also, as to NMS, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of entrectinib and RXDX-102, and include the right to grant sublicenses. We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize a product based on either or both of entrectinib and RXDX-102, at our expense.
		Under the terms of the license agreement, on November 6, 2013, we issued to NMS a warrant to acquire up to 16,667 shares of our common stock, which has an exercise price of $6.00 per share and is exercisable at any time at the option of the holder until November 6, 2018. The terms of the license agreement also provided for an up-front payment to NMS of $7.0 million which was paid in November 2013 and expensed to research and development as no future benefit was determined at that time. When and if commercial sales of a product based on either or both of entrectinib or RXDX-102 begin, we will be obligated to pay NMS tiered royalties ranging from a mid-single digit percentage to a low double digit percentage (between 10% and 15%) of our net sales, depending on the amount of our net sales, with standard provisions for royalty offsets to the extent we obtain any rights from third parties to commercialize the product. We were also obligated under the terms of the license agreement to engage NMS to perform services valued at $1.0 million prior to December 31, 2014 which obligation had been met prior to year-end. The license agreement also requires that we make development and regulatory milestone payments to NMS of up to $105.0 million in the aggregate if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications. Pursuant to the December 2014 amendment to the agreement, we paid the initial milestone payment of $10.0 million to NMS in December 2014, which was expensed to research and development as no future benefit was determined at that time.
		On August 4, 2014, we entered into a second license agreement with NMS. The agreement grants us exclusive global rights to develop and commercialize RXDX-103, as well as a second development program, RXDX-104. Based on preclinical activities relating to RXDX-104, in December 2014 we decided to discontinue development of RXDX-104, and we will not devote further development resources to this program.
		Our rights under the agreement are exclusive for the term of the agreement with respect to RXDX-103 and RXDX-104 and also, as to NMS, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of RXDX-103 and RXDX-104, subject to NMS’s right to develop and commercialize a predecessor compound to RXDX-103 solely for animal indications. We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize a product based on either or both of RXDX-103 and RXDX-104, at our expense.
		Under the license agreement, we made an up-front payment to NMS of $3.5 million in August 2014, which was expensed to research and development as no future benefit was determined at that time. When and if commercial sales of a product based on either of RXDX-103 or RXDX-104 begin, we will be obligated to pay NMS tiered royalties ranging from a mid-single digit percentage to a low double digit percentage of net sales, depending on annual amounts of net sales, with standard provisions for royalty offsets to the extent we are required to obtain any rights from third parties to commercialize either RXDX-103 or RXDX-104. We are also required to make development and regulatory milestone payments to NMS of up to $102.0 million in the aggregate if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications.
		On March 31, 2014, the Company entered into an agreement with a contract research organization for clinical studies to be conducted both within and outside the U.S., at an estimated cost of approximately $10 million over a two-year period. Through December 31, 2014, approximately $1.9 million has been incurred.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Concentrations	12. Concentrations
	Credit risk	The Company maintains cash balances at various financial institutions. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. At times these balances exceed federally insured limits. The Company has not experienced any losses in such accounts.
		With respect to our available-for-sale securities, our primary exposure to market risk is interest rate sensitivity. This means that a change in prevailing interest rates may cause the value of the investment to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of our investment will probably decline. Currently, our holdings are in money market funds and available-for-sale securities, and therefore this interest rate risk is minimal. To minimize our interest rate risk going forward, we intend to continue to maintain our portfolio of cash, cash equivalents and available-for-sale securities in a variety of securities consisting of money market funds and debt securities, all with various maturities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. We also generally time the maturities of our investments to correspond with our expected cash needs, allowing us to avoid realizing any potential losses from having to sell securities prior to their maturities.
		Our cash is invested in accordance with a policy approved by our Board of Directors which specifies the categories, allocations, and ratings of securities we may consider for investment. We do not believe our cash, cash equivalents and available-for-sale securities have significant risk of default or illiquidity. We made this determination based on discussions with our treasury managers and a review of our holdings. While we believe our cash, cash equivalents and available-for-sale securities are well diversified and do not contain excessive risk, we cannot provide absolute assurance that our investments will not be subject to future adverse changes in market value.

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Parties	13. Related Parties	In 2012, the Company executed an employee lease agreement with its majority stockholder. Under the terms of the agreement, the Company is reimbursed for certain administrative services provided to the related party. In addition, the Company was reimbursed for various operating expenses related to shared utilities and telecommunications and/or may make payments to its majority shareholder for these shared operating expenses.
		Total reimbursements received during the years ended December 31, 2014 and 2013 was $0 and $5,704, respectively. There was $0 in accounts receivable at December 31, 2014 and 2013, respectively. Total payments made during the years ended December 31, 2014 and 2013 was $1,165 and $23,723, respectively.
		In May 2013, the Company and Actagene effected a merger pursuant to which Actagene merged with and into the Company. The majority stockholder of Ignyta was also the majority stockholder of Actagene, and representatives of the majority stockholder controlled the day to day operations and were on the board of directors of each entity (see Note 3).

401k_Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2014
Postemployment Benefits [Abstract]
401(k) Plan	14. 401(k) Plan	In 2014, the Company established a defined contribution plan, organized under Section 401(k) of the Internal Revenue Code, which allows employees who have completed at least one month of service and have reached age 21 to defer up to 100% of their pay on a pre-tax basis. The Company does not contribute a match to the employees’ contribution.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events
	Restricted Stock Units	In 2015, the Company issued 90,000 Restricted Stock Units to employees under the 2014 Plan with vesting to occur on either the 4 year or 5 year anniversary of the grant date.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of operations	Nature of operations	Ignyta, Inc. (“Ignyta”) was founded in 2011 and is incorporated in the state of Delaware. On June 12, 2014, Ignyta, Inc., a corporation incorporated in the state of Nevada, merged with and into Ignyta (then known as Ignyta Operating, Inc.) with Ignyta Operating, Inc. surviving the merger and changing its name to Ignyta, Inc. (see Note 2).
		On October 31, 2013, Ignyta merged with and into IGAS Acquisition Corp., a wholly-owned subsidiary of Ignyta, Inc., a Nevada corporation previously named Infinity Oil & Gas Company (see Note 2). As used in these financial statements, unless the context indicates or otherwise requires, the “Company”, “we”, “us”, and “our” refer to Ignyta.
		In May 2013, the Company acquired Actagene Oncology, Inc. (“Actagene”), a San Diego based privately held biotechnology company developing precision medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. With the acquisition, the Company changed its business strategy from a prior focus on molecular diagnostics for autoimmune disease to an integrated drug and diagnostic, or Rx/Dx, focus on drug and biomarker discovery and development for oncology (see Note 3).
		The Company is a precision oncology biotechnology company dedicated to discovering or acquiring, then developing and commercializing, targeted new drugs for cancer patients whose tumors harbor specific molecular alterations. The Company is pursuing an integrated therapeutic and diagnostic, or Rx/Dx, strategy, where it anticipates pairing each of its product candidates with biomarker-based companion diagnostics that are designed to identify the patients who are most likely to benefit from the precisely targeted drugs the Company develops.
Liquidity	Liquidity	As of December 31, 2014, the Company had an accumulated deficit of approximately $55,563,000. The Company also had negative cash flow from operations of approximately $32,488,000 during the twelve months ended December 31, 2014.
		The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products.
		We are currently focused primarily on the development of our entrectinib, RXDX-103 and Spark programs. We believe such activities will result in our continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of our products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing. We cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
		While we expect that our existing cash, cash equivalents and available-for-sale securities will enable us to fund our operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require us to delay, reduce, limit or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Use of estimates	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation allowance on deferred tax assets, the valuation of warrants, the useful life of assets and those assumed in calculating stock-based compensation expense.
Cash and cash equivalents	Cash and cash equivalents
	The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
Investments	Investments
	Investments consist of corporate notes and bonds and commercial paper. The Company classifies investments as available-for-sale at the time of purchase. All investments are recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investments as of each balance sheet date to assess whether those with unrealized loss positions are other-than-temporarily impaired. Impairments are considered to be other-than-temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of its cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the Statements of Operations. No other-than-temporary impairment charges have been recognized since inception.
Fixed assets	Fixed assets
	Fixed assets are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to seven years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
Impairment of long-lived assets	Impairment of long-lived assets
	In accordance with authoritative guidance related to impairment or disposal of long-lived assets, management reviews the Company’s long-lived asset groups for impairment whenever events indicate that their book value may not be recoverable. When management determines that one or more impairment indicators are present for an asset group, it compares the book value of the asset group to net future undiscounted cash flows that the asset group is expected to generate. If the book value of the asset group is greater than the net future undiscounted cash flows that the asset group is expected to generate, it compares the fair value to the book value of the asset group. If the fair value is less than the book value, it recognizes an impairment loss. The impairment loss would be the excess of the book value of the asset group over its fair value. To date, the Company has not experienced any impairment losses on its long-lived assets used in operations.
Stock-based compensation	Stock-based compensation	The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
		The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Fair value of financial instruments	Fair value of financial instruments
	The Company’s financial instruments consist of cash and cash equivalents, investments, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of December 31, 2014 and December 31, 2013, the book values are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Derivative liabilities	Derivative liabilities
	The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future events, expected volatility, expected life, yield, and risk free interest rate.
Income taxes	Income taxes
	Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
Earnings per share ("EPS")	Earnings per share (“EPS”)
	Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted EPS calculations are the same since the increased number of shares that would be included in the diluted calculation from the assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the financial statements.
Comprehensive income (loss)	Comprehensive income (loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported net of their related tax effect, to arrive at comprehensive income (loss).
Research and development costs	Research and development costs
	The Company is actively engaged in new product development efforts for which related costs are expensed as incurred.
Fair value measurement	Fair value measurement	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
		The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013 (in thousands):
			December 31, 2014								December 31, 2013
			Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents		$	6,346	$	—	$	—	$	6,346	$	51,804	$	—	$	—	$	51,804
	Short-term investments:
	Corporate debt securities
	Financial			—		34,788		—		34,788		—		—		—		—
	Industrial			—		17,503		—		17,503		—		—		—		—
	Utility			—		7,014		—		7,014		—		—		—		—
	Commercial paper
	Financial			—		3,896		—		3,896		—		—		—		—
	Industrial			—		—		—		—		—		—		—		—
	Total short-term investments		$	—	$	63,201	$	—	$	63,201	$	—	$	—	$	—	$	—
	Long-term investments:
	Corporate debt securities
	Financial			—		3,230		—		3,230		—		—		—		—
	Industrial			—		3,857		—		3,857		—		—		—		—
	Utility			—		—		—		—		—		—		—		—
	Total long-term investments		$	—	$	7,087	$	—		7,087	$	—	$	—	$	—	$	—
	Total assets measured at fair value		$	6,346	$	70,288	$	—	$	76,634	$	51,804	$	—	$	—	$	51,804
	Liabilities:
	Warrant liability			—		—		—		—		—		—		129		129
	Total liabilities measured at fair value		$	—	$	—	$	—	$	—	$	—	$	—	$	129	$	129
		The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its debt securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.
		The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The warrants were reclassified to equity during the year due to the removal of the anti dilution provision in the Articles of Incorporation as referenced in the warrant agreements (see Note 9).

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013 (in thousands):
		December 31, 2014								December 31, 2013
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	6,346	$	—	$	—	$	6,346	$	51,804	$	—	$	—	$	51,804
	Short-term investments:
	Corporate debt securities
	Financial		—		34,788		—		34,788		—		—		—		—
	Industrial		—		17,503		—		17,503		—		—		—		—
	Utility		—		7,014		—		7,014		—		—		—		—
	Commercial paper
	Financial		—		3,896		—		3,896		—		—		—		—
	Industrial		—		—		—		—		—		—		—		—
	Total short-term investments	$	—	$	63,201	$	—	$	63,201	$	—	$	—	$	—	$	—
	Long-term investments:
	Corporate debt securities
	Financial		—		3,230		—		3,230		—		—		—		—
	Industrial		—		3,857		—		3,857		—		—		—		—
	Utility		—		—		—		—		—		—		—		—
	Total long-term investments	$	—	$	7,087	$	—		7,087	$	—	$	—	$	—	$	—
	Total assets measured at fair value	$	6,346	$	70,288	$	—	$	76,634	$	51,804	$	—	$	—	$	51,804
	Liabilities:
	Warrant liability		—		—		—		—		—		—		129		129
	Total liabilities measured at fair value	$	—	$	—	$	—	$	—	$	—	$	—	$	129	$	129

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Summary of Investments by Security Type	The following table summarizes investments by security type as of December 31, 2014:
		December 31, 2014 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Corporate debt securities, short-term	$	63,239	$	—	$	(38	)	$	63,201
	Corporate debt securities, long-term	$	7,102	$	—	$	(15	)	$	7,087
	Total	$	70,341	$	—	$	(53	)	$	70,288

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Components of Fixed Assets	Fixed assets consisted of the following:
		December 31,			December 31,
		2014			2013
	Manufacturing and lab equipment	$	3,837,967		$	775,872
	Office furniture		278,895			59,095
	Computers and equipment		358,964			110,857
	Software		112,451			—
	Leasehold Improvements		2,326,963			—
			6,915,240			945,824
	Less accumulated depreciation and amortization		(634,331	)		(115,118	)
		$	6,280,909		$	830,706

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Future Minimum Principal Payments on Notes Payable		Future minimum principal payments on notes payable are as follows:
	Twelve Months ending December 31,
	2015		$	1,400,000
	2016			8,400,000
	2017			8,400,000
	2018			2,800,000
	Total		$	21,000,000

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity and Related Information	A summary of the Company’s stock option activity and related information is as follows:
		Options			Weighted-			Weighted-		Aggregate
		Outstanding			Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Balance at December 31, 2012		156,659		$	0.36			—	$	—
	Granted		1,061,325			4.6			—		—
	Exercised		(12,290	)		0.24			—		—
	Expired		(2,154	)		0.54			—		—
	Forfeited		(70,387	)		0.45			—		—
	Balance at December 31, 2013		1,133,153		$	4.33			9.71	$	3,026,430
	Granted		2,300,000			7.89			—		—
	Exercised		(18,143	)		0.38			—		—
	Expired		(4,999	)		0.58			—		—
	Forfeited		(418,355	)		7.43			—		—
	Balance at December 31, 2014		2,991,656		$	6.67			9.21	$	2,482,181
	Exercisable at December 31, 2014		369,705		$	3.59			8.55	$	1,212,411
Assumptions Used to Estimate Fair Value of Options Granted	The fair value of options granted to employees and non-employee directors was estimated at the date of grant using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		December 31,			December 31,
		2014			2013
	Risk free interest rate		1.83	%		1.92	%
	Dividend yield		0	%		0	%
	Volatility		65.24	%		59.26	%
	Weighted-average expected life of option (years)		6			6.1
	The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		December 31,			December 31,
		2014			2013
	Risk free interest rate		2.1	%		2.61	%
	Dividend yield		0	%		0	%
	Volatility		68.01	%		58.16	%
	Weighted-average expected life of option (years)		9.35			10

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Property Held Under Current Capital Leases	As of December 31, 2014, property held under the current capital leases was as follows:
		December 31,
		2014
	Lab equipment	$	635,730
			635,730
	Less accumulated depreciation and amortization		(16,716	)
	Total	$	619,014
Future Minimum Payments Under Capital Leases	As of December 31, 2014, future minimum payments under all capital leases are as follows:
	Twelve Months ending December 31,	Lease Payment
	2015	$	194,002
	2016		194,002
	2017		167,474
	Total minimum payments	$	555,478
	Less amounts representing interest		(39,652	)
	Present value of net minimum payments	$	515,826
	Less current portion		(171,638	)
	Long-term capital lease obligations	$	344,188
Future Minimum Lease Payments Under Operating Leases	Future minimum lease payments required under the operating leases are as follows:
	Twelve Months Ending December,
	2015	$	712,400
	2016		770,500
	2017		769,900
	2018		793,000
	2019		679,300
	Thereafter		—
	Total	$	3,725,100

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended		40 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014
Accounting Policies [Line Items]
Retained Earnings (Accumulated Deficit)	$55,562,586	$15,572,940	$55,562,586
Net cash used in operating activities	32,487,841	13,073,072
Other-than-temporary impairment charges			$0
Minimum [Member]
Accounting Policies [Line Items]
Property, plant and equipment, useful life	3 years
Maximum [Member]
Accounting Policies [Line Items]
Property, plant and equipment, useful life	7 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:
Cash and cash equivalents	$6,346	$51,804
Total assets measured at fair value	76,634	51,804
Liabilities:
Warrant liability		129
Total liabilities measured at fair value		129
Short-Term Investments [Member]
Assets:
Investments	63,201
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]
Assets:
Investments	34,788
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]
Assets:
Investments	17,503
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]
Assets:
Investments	7,014
Short-Term Investments [Member] | Commercial Paper [Member] | Financial [Member]
Assets:
Investments	3,896
Long-Term Investments [Member]
Assets:
Investments	7,087
Long-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]
Assets:
Investments	3,230
Long-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]
Assets:
Investments	3,857
Level 1 [Member]
Assets:
Cash and cash equivalents	6,346	51,804
Total assets measured at fair value	6,346	51,804
Level 2 [Member]
Assets:
Total assets measured at fair value	70,288
Level 2 [Member] | Short-Term Investments [Member]
Assets:
Investments	63,201
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]
Assets:
Investments	34,788
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]
Assets:
Investments	17,503
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]
Assets:
Investments	7,014
Level 2 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Financial [Member]
Assets:
Investments	3,896
Level 2 [Member] | Long-Term Investments [Member]
Assets:
Investments	7,087
Level 2 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]
Assets:
Investments	3,230
Level 2 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]
Assets:
Investments	3,857
Level 3 [Member]
Liabilities:
Warrant liability		129
Total liabilities measured at fair value		$129

Reverse_Merger_Additional_Info

Reverse Merger - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Oct. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Merger closure date		31-Oct-13
Conversion basis of preferred stock to common stock		One-to-one
Reverse stock split conversion ratio	0.01
Common Stock, shares outstanding		19,584,769	13,934,876
Share based compensation, Outstanding option		2,991,656	1,133,153	156,659
Series A Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Reverse stock split conversion ratio	0.3333
Merger Transactions [Member]
Business Acquisition [Line Items]
Conversion basis of preferred stock to common stock		One-to-one
Preferred stock conversion ratio	1
Common Stock, shares outstanding	4,916,469
Ownership percentage by former stockholders of Ignyta	99.85%
Shares reserved for issuance pursuant to future equity grants	342,209
Merger Transactions [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Warrants to purchase stock, outstanding	25,001
Merger Transactions [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Number of securities called by warrants	25,001
Merger Transactions [Member] | 2011 Equity Incentive Plan [Member]
Business Acquisition [Line Items]
Share based compensation, Outstanding option	358,986
Merger Transactions [Member] | Series A Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Reverse stock split conversion ratio	0.3333
Reverse stock split ratio		Three-to-one

Actagene_Merger_Additional_Inf

Actagene Merger - Additional Information (Detail)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2011	20-May-13
Business Acquisition [Line Items]
Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene		666,668
Merger closure date	31-Oct-13
Actagene Merger [Member]
Business Acquisition [Line Items]
Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene			1,583,336
Merger closure date	20-May-13
Percentage of voting power in each entity			60.00%

Investments_Summary_of_Investm

Investments - Summary of Investments by Security Type (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	$70,341
Available-for-sale securities, Gross Unrealized Gains	0
Available-for-sale securities, Gross Unrealized Losses	-53
Available-for-sale securities, Fair Market Value	70,288
Corporate Debt Securities [Member] | Short Term Debt [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	63,239
Available-for-sale securities, Gross Unrealized Gains	0
Available-for-sale securities, Gross Unrealized Losses	-38
Available-for-sale securities, Fair Market Value	63,201
Corporate Debt Securities [Member] | Long Term Debt [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	7,102
Available-for-sale securities, Gross Unrealized Gains	0
Available-for-sale securities, Gross Unrealized Losses	-15
Available-for-sale securities, Fair Market Value	$7,087

Fixed_Assets_Components_of_Fix

Fixed Assets - Components of Fixed Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Manufacturing and lab equipment	$3,837,967	$775,872
Office furniture	278,895	59,095
Computers and equipment	358,964	110,857
Software	112,451
Leasehold Improvements	2,326,963
Fixed Assets - Gross	6,915,240	945,824
Less accumulated depreciation and amortization	-634,331	-115,118
Fixed Assets - Net	$6,280,909	$830,706

Fixed_Assets_Additional_Inform

Fixed Assets - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation	$527,675	$112,380

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 19, 2014	Sep. 30, 2014	Jul. 31, 2013	Feb. 27, 2013	Jun. 30, 2012
Debt Instrument [Line Items]
Loan, maximum borrowing amount		$21,000,000
Loan, additional borrowing option		10,000,000
Final loan fee recorded as debt discount	630,000	1,050,000
Percentage of principal amount of new loan to be paid as final payment		3.00%
Principal and interest payment period commencing after period of interest only payments		30 months
Interest only payments period	12 months
Fixed interest on the advanced amount		8.56%
New loan agreement maturity date		1-Apr-18
Proceeds form offering of equity securities	50,000,000
Final loan payment, paid in full	1,050,000
Warrants issued with debt financing recorded as debt discount		28,300	24,500
Interest expense due to amortization of the debt discount	287,863	48,470
Common Stock [Member]
Debt Instrument [Line Items]
Proceeds form offering of equity securities				55,200,000
Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Warrant to purchase stock, shares			8,334			16,667	16,667	8,334
Warrant exercise price per share			$3				$3
Percentage of prior loan agreement up to a number of stock on which warrant to purchase common stock issued							5.00%
New Loan Agreement [Member]
Debt Instrument [Line Items]
Contingency payments default interest rate	11.56%
New Loan Agreement [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Warrant to purchase stock, shares	37,849				37,849
Warrants valued using binomial model	208,400
Warrant exercise price per share	$7.52				$7.52
Useful life	7 years
Warrant to purchase stock,shares	135,500
Loan Agreement [Member]
Debt Instrument [Line Items]
Loan, maximum borrowing amount		10,000,000					1,500,000
Final loan fee recorded as debt discount		1,050,000
Final loan payment, paid in full					$1,050,000

Notes_Payable_Future_Minimum_P

Notes Payable - Future Minimum Principal Payments on Notes Payable (Detail) (USD $)	Dec. 31, 2014
Debt Disclosure [Abstract]
2015	$1,400,000
2016	8,400,000
2017	8,400,000
2018	2,800,000
Total	$21,000,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended		12 Months Ended		0 Months Ended	12 Months Ended
	Oct. 31, 2013	Dec. 31, 2014	Nov. 29, 2013	Nov. 06, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 19, 2014	Dec. 31, 2013	Oct. 30, 2013
			Investor	Investor
Class of Stock [Line Items]
Common Stock, shares authorized		150,000,000						150,000,000
Preferred Stock, shares authorized		10,000,000						10,000,000
Common Stock, voting right description		Common stock is entitled to one vote, and all shares rank equally as to voting and other matters.
Gross proceeds from sale of stock		$50,000,000
Reverse stock split ratio	0.01
Common Stock, par value	$0.00	$0.00						0.0001	$0.00
Conversion basis of preferred stock to common stock		One-to-one
Private Investment in Public Equity ( the "PIPE" Financing") [Member]
Class of Stock [Line Items]
Number of accredited investors			195	52
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued					416,667	416,667
Reverse stock split ratio	0.3333
Issuance of Preferred Stock, price per share					$0.60	$0.60
Proceeds from issuance of preferred stock					250,000	250,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued					1,835,000
Issuance of Preferred Stock, price per share					$3
Proceeds from issuance of preferred stock					5,505,000
Common Stock [Member]
Class of Stock [Line Items]
Stock issued		6,031,750					6,031,750	9,010,238
Sales of common stock, price per share							$9.15
Gross proceeds from sale of stock							55,200,000
Common Stock [Member] | Private Investment in Public Equity ( the "PIPE" Financing") [Member]
Class of Stock [Line Items]
Stock issued			1,270,096	7,740,142
Sales of common stock, price per share			6	6
Gross proceeds from sale of stock			7,600,000	46,400,000

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended				0 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	20-May-13	Feb. 28, 2014	Jun. 11, 2014	Oct. 31, 2013	Feb. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial share reserve						1,000,000
Common stock available for issuance		2,712,652		166,666				712,652	666,666
Stock-based compensation expense for employees and non-employees	$2,056,027	$351,159
Unrecognized compensation cost related to unvested stock-based awards	9,782,363
Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene				666,668
Proceed from sale of shares of restricted stock	51,581,842	51,013,741		2,000
Shares of common stock repurchased			13,334
Stock-based compensation, restricted stock	64,255	19,280
Actagene Merger [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene					1,583,336
Shares of restricted stock, vested	1,150,928				1,000,000
Shares of restricted stock, unvested	32,408					183,336
Shares of common stock repurchased						400,000
Stock-based compensation, restricted stock	162,323	0
Shares vesting period	4 years
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	668,932	220,888
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	$1,387,095	$130,271
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated weighted-average fair value of stock options granted	$4.70	$2.83
Unrecognized compensation cost related to unvested stock-based awards, weighted average period of recognition	3 years 3 months 11 days
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration period from their date of grant	10 years
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total combined voting power	10.00%
Exercise price of option as a percentage of fair market value of common Stock on the grant date	100.00%
Stock Options [Member] | Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted, term	5 years
Stock Options [Member] | Stock Option One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of option as a percentage of fair market value of common Stock on the grant date	110.00%
Stock Options [Member] | 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued for each share subject to a stock option outstanding	1
Common stock reserved for issuance	3,000,000
Shares that remained available for grant	2,233,319
Stock Options [Member] | 2011 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	2,712,652
Stock Options [Member] | Inducement Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	1,000,000
Number of additional equity grants	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock, vested	639,337			600,000
Shares of restricted stock, unvested	13,997			66,668
Employee and Non-employee Stock Options [Member] | 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of equity awards							3,000,000
Employee and Non-employee Stock Options [Member] | 2011 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued for each share subject to a stock option outstanding							1
Non-Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated weighted-average fair value of stock options granted	$6.65	$1.59
Options granted during period, maximum contractual term	9 years 4 months 6 days	10 years
Non-Employee Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period, maximum contractual term	10 years

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Options Outstanding
Balance at beginning of period	1,133,153	156,659
Granted	2,300,000	1,061,325
Exercised	-18,143	-12,290
Expired	-4,999	-2,154
Forfeited	-418,355	-70,387
Balance at end of period	2,991,656	1,133,153
Exercisable at end of period	369,705
Weighted-Average Exercise Price
Balance at beginning of period	$4.33	$0.36
Granted	$7.89	$4.60
Exercised	$0.38	$0.24
Expired	$0.58	$0.54
Forfeited	$7.43	$0.45
Balance at end of period	$6.67	$4.33
Exercisable at end of period	$3.59
Weighted- Average Remaining Contractual Term
Balance at end of period	9 years 2 months 16 days	9 years 8 months 16 days
Exercisable at end of period	8 years 6 months 18 days
Aggregate Intrinsic Value
Balance at end of period	$2,482,181	$3,026,430
Exercisable at end of period	$1,212,411

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Options Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Non-Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.10%	2.61%
Dividend yield	0.00%	0.00%
Volatility	68.01%	58.16%
Weighted-average expected life of option (years)	9 years 4 months 6 days	10 years
Employee and Non-employee Directors Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.83%	1.92%
Dividend yield	0.00%	0.00%
Volatility	65.24%	59.26%
Weighted-average expected life of option (years)	6 years	6 years 1 month 6 days

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Jul. 31, 2013	Feb. 27, 2013	Dec. 31, 2012	Jun. 30, 2012	Nov. 06, 2013
Class of Warrant or Right [Line Items]
Warrant expense		$47,600
Warrant reclassified due to removal of anti-dilution provision	125,000
New Loan Agreement [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase stock, shares	37,849		37,849
Number of warrants issued			2
Warrant exercise price per share	$7.52		$7.52
Warrant exercise period	30-Sep-21
Warrants valued using binomial model	208,400
Exercise price	$7.52
Risk-free interest rate	2.22%
Expected volatility	69.70%
Useful life	7 years
Series B Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase stock, shares				16,667	16,667	8,334	8,334
Warrant exercise price per share					$3	$3
Percentage of prior loan agreement up to a number of stock on which warrant to purchase common stock issued					5.00%
Warrant expiry date	27-Feb-20
Licensing Agreements [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase stock, shares								16,667
Warrant exercise price per share								$6
Warrant exercise period	6-Nov-18
Exercise price	$6
Risk-free interest rate	1.68%
Expected volatility	54.80%
Useful life	4 years 10 months 6 days
Warrant expense	$47,600

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Non-current deferred tax asset	$22,828,000	$6,008,000
Valuation allowance	22,828,000
Valuation allowance increase during period	16,820,000
Operating loss and credit carryforwards limitation	Net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within a three-year period.
Federal [Member]
Income Tax [Line Items]
Net operating losses	33,015,000
Tax credit carry forwards	794,000
Net credit carryforwards, beginning period of expiration	2031
State and Local [Member]
Income Tax [Line Items]
Net operating losses	32,134,000
California [Member]
Income Tax [Line Items]
Tax credit carry forwards	$859,000
Federal and California [Member]
Income Tax [Line Items]
Net operating loss carryforwards, beginning period of expiration	2031
Florida and Massachusetts [Member]
Income Tax [Line Items]
Net operating loss carryforwards, beginning period of expiration	2034

Commitments_and_Contingencies_1

Commitments and Contingencies - Property Held Under Current Capital Leases (Detail) (USD $)	Dec. 31, 2014
Capital Leased Assets [Line Items]
Capital leased assets gross	$635,730
Less accumulated depreciation and amortization	-16,716
Total	619,014
Lab Equipment [Member]
Capital Leased Assets [Line Items]
Capital leased assets gross	$635,730

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 04, 2014	Nov. 06, 2013	Dec. 31, 2014	Mar. 31, 2014
Loss Contingencies [Line Items]
Depreciation expense	$16,716	$0
License agreement term	5 years
Additional clinical expenses	1,900,000				1,900,000	10,000,000
Estimated cost period	Over a two-year period
Licensing Agreements [Member]
Loss Contingencies [Line Items]
Annual license payments			3,500,000	7,000,000	10,000,000
Contingent milestone payments			102,000,000
Licensing Agreements [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Amount of service to be performed by NMs under the agreement				1,000,000
Royalties percentage				10.00%
Licensing Agreements [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Contingent milestone payments				105,000,000
Royalties percentage				15.00%
Licensing Agreements [Member] | Common Stock [Member]
Loss Contingencies [Line Items]
Warrant to purchase stock, shares				16,667
Warrant to purchase stock, exercise price per share				$6
Warrant to purchase stock, exercisable date				6-Nov-18
Office Building [Member]
Loss Contingencies [Line Items]
Operating leases, rent expense	406,357	146,952
Operating leases, expiration dates	Operating leases expiring on various dates through October 2019.
Lab Equipment [Member]
Loss Contingencies [Line Items]
Operating leases, rent expense	88,504	60,620
Operating leases, expiration dates	Operating lease that expires in March 2016.
Operating leases, monthly rental payment	$5,758

Commitments_and_Contingencies_3

Commitments and Contingencies - Future Minimum Payments Under Capital Leases (Detail) (USD $)	Dec. 31, 2014
Leases [Abstract]
2015	$194,002
2016	194,002
2017	167,474
Total minimum payments	555,478
Less amounts representing interest	-39,652
Present value of net minimum payments	515,826
Less current portion	-171,638
Long-term capital lease obligations	344,188
Present value of net minimum payments	$515,826

Commitments_and_Contingencies_4

Commitments and Contingencies - Future Minimum Lease Payments Under Operating Leases (Detail) (USD $)	Dec. 31, 2014
Leases [Abstract]
2015	$712,400
2016	770,500
2017	769,900
2018	793,000
2019	679,300
Thereafter	0
Total	$3,725,100

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (Majority Stockholder [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Majority Stockholder [Member]
Related Party Transaction [Line Items]
Total reimbursements received	$0	$5,704
Accounts receivable	0	0
Total payments	$1,165	$23,723

401k_Plan_Additional_Informati

401(k) Plan - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
Schedule Of Sale Of Subsidiary [Abstract]
Eligible days of service	21 years
Employer matching contribution percentage	0.00%
Employees contribution percentage	100.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	12 Months Ended	0 Months Ended
	Dec. 31, 2011	Jan. 01, 2015
Schedule of Reverse Stock Split [Line Items]
Issuance of Restricted Stock	666,668
Subsequent Event [Member] | 2014 Plan [Member]
Schedule of Reverse Stock Split [Line Items]
Issuance of Restricted Stock		90,000
Subsequent Event [Member] | 2014 Plan [Member] | Minimum [Member]
Schedule of Reverse Stock Split [Line Items]
Vesting period of restricted stock		4 years
Subsequent Event [Member] | 2014 Plan [Member] | Maximum [Member]
Schedule of Reverse Stock Split [Line Items]
Vesting period of restricted stock		5 years